Tempest Therapeutics Board Member Resigns Amidst Financial and Nasdaq Compliance Issues
TPST is trading near its 52-week low of $1.5 (4.3% above the low).
Summary
Shiri Simantov has resigned from Tempest Therapeutics' Board of Directors, effective May 23, 2026. This departure adds to a series of recent negative developments for the micro-cap biotech, including a Q1 2026 net loss of $27.7 million, a reiterated 'going concern' warning, and multiple Nasdaq deficiency notices received on May 22nd. The resignation, with no reason disclosed, further highlights the company's current instability and precarious financial position.
At the time of this announcement, TPST was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $1.50 to $12.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.